Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss
Background: Female pattern hair loss (FPHL) has a negative psychological and social impact. Lacks of consensus for its treatment as well as inconsistent response to treatment modalities are considered major challenges for physicians. Objectives: To assess the safety and efficacy of oral finasteride...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Clinical Dermatology Review |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/cdr.cdr_87_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087756319227904 |
|---|---|
| author | Eman Hamed El Morsy Asmaa Saad Abd Toto Eman Mohamed Hassan |
| author_facet | Eman Hamed El Morsy Asmaa Saad Abd Toto Eman Mohamed Hassan |
| author_sort | Eman Hamed El Morsy |
| collection | DOAJ |
| description | Background:
Female pattern hair loss (FPHL) has a negative psychological and social impact. Lacks of consensus for its treatment as well as inconsistent response to treatment modalities are considered major challenges for physicians.
Objectives:
To assess the safety and efficacy of oral finasteride 5 mg and 2 mg versus topical minoxidil 5% in FPHL both clinically and by trichoscopy.
Patients and Methods:
Forty-five females with FPHL were included in the study for 6-month duration. Fifteen patients in Group A received oral finasteride 5 mg daily, 15 patients in Group B received oral finasteride 2 mg daily, and 15 patients in Group C were treated with topical minoxidil 5% solution. Assessment was done using Sinclair scale, photography, trichoscopy, degree of improvement, and patient satisfaction scale.
Results:
Significant improvement of Sinclair scale, hair density, and yellow dots in each group was noted along the treatment period; however, no further improvement of hair density in Group B after the 3rd month was detected. There was significant higher improvement in the hair density in Group A and C than Group B. The degree of improvement and patient satisfaction were significantly greater in Group A and C than Group B. A negative correlation between degree of improvement and patient’s age was observed in Group B.
Conclusion:
Oral finasteride 5 mg and topical minoxidil 5% gave comparable results in FPHL, yet both provided greater and maintained response than 2 mg finasteride. In addition, low-dose finasteride gave better responses in the younger age group. However, all three treatment options were safe in the treatment of FPHL. |
| format | Article |
| id | doaj-art-7a7fe89d86f5426a83ca7deb4145b71d |
| institution | Kabale University |
| issn | 2542-551X 2542-5528 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Clinical Dermatology Review |
| spelling | doaj-art-7a7fe89d86f5426a83ca7deb4145b71d2025-02-06T05:07:41ZengWolters Kluwer Medknow PublicationsClinical Dermatology Review2542-551X2542-55282025-01-0191455210.4103/cdr.cdr_87_24Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair LossEman Hamed El MorsyAsmaa Saad Abd TotoEman Mohamed HassanBackground: Female pattern hair loss (FPHL) has a negative psychological and social impact. Lacks of consensus for its treatment as well as inconsistent response to treatment modalities are considered major challenges for physicians. Objectives: To assess the safety and efficacy of oral finasteride 5 mg and 2 mg versus topical minoxidil 5% in FPHL both clinically and by trichoscopy. Patients and Methods: Forty-five females with FPHL were included in the study for 6-month duration. Fifteen patients in Group A received oral finasteride 5 mg daily, 15 patients in Group B received oral finasteride 2 mg daily, and 15 patients in Group C were treated with topical minoxidil 5% solution. Assessment was done using Sinclair scale, photography, trichoscopy, degree of improvement, and patient satisfaction scale. Results: Significant improvement of Sinclair scale, hair density, and yellow dots in each group was noted along the treatment period; however, no further improvement of hair density in Group B after the 3rd month was detected. There was significant higher improvement in the hair density in Group A and C than Group B. The degree of improvement and patient satisfaction were significantly greater in Group A and C than Group B. A negative correlation between degree of improvement and patient’s age was observed in Group B. Conclusion: Oral finasteride 5 mg and topical minoxidil 5% gave comparable results in FPHL, yet both provided greater and maintained response than 2 mg finasteride. In addition, low-dose finasteride gave better responses in the younger age group. However, all three treatment options were safe in the treatment of FPHL.https://journals.lww.com/10.4103/cdr.cdr_87_24female pattern hair lossfinasterideminoxidil |
| spellingShingle | Eman Hamed El Morsy Asmaa Saad Abd Toto Eman Mohamed Hassan Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss Clinical Dermatology Review female pattern hair loss finasteride minoxidil |
| title | Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss |
| title_full | Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss |
| title_fullStr | Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss |
| title_full_unstemmed | Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss |
| title_short | Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss |
| title_sort | oral finasteride 5 mg and 2 mg versus topical minoxidil 5 in female pattern hair loss |
| topic | female pattern hair loss finasteride minoxidil |
| url | https://journals.lww.com/10.4103/cdr.cdr_87_24 |
| work_keys_str_mv | AT emanhamedelmorsy oralfinasteride5mgand2mgversustopicalminoxidil5infemalepatternhairloss AT asmaasaadabdtoto oralfinasteride5mgand2mgversustopicalminoxidil5infemalepatternhairloss AT emanmohamedhassan oralfinasteride5mgand2mgversustopicalminoxidil5infemalepatternhairloss |